DK3284520T3 - Polycyklisk carbamoylpyridonderivat med hiv-integrase-hæmmende aktivitet - Google Patents

Polycyklisk carbamoylpyridonderivat med hiv-integrase-hæmmende aktivitet Download PDF

Info

Publication number
DK3284520T3
DK3284520T3 DK17195280.7T DK17195280T DK3284520T3 DK 3284520 T3 DK3284520 T3 DK 3284520T3 DK 17195280 T DK17195280 T DK 17195280T DK 3284520 T3 DK3284520 T3 DK 3284520T3
Authority
DK
Denmark
Prior art keywords
hiv integrase
pyridone derivatives
inhibitive activity
polycyclic
carbamoyl pyridone
Prior art date
Application number
DK17195280.7T
Other languages
Danish (da)
English (en)
Inventor
Brian Alvin Johns
Yoshiyuki Taoda
Takashi Kawasuji
Teruhiko Taishi
Original Assignee
Viiv Healthcare Co
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3284520(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Co, Shionogi & Co filed Critical Viiv Healthcare Co
Application granted granted Critical
Publication of DK3284520T3 publication Critical patent/DK3284520T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17195280.7T 2005-04-28 2006-04-28 Polycyklisk carbamoylpyridonderivat med hiv-integrase-hæmmende aktivitet DK3284520T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005131161 2005-04-28
JP2005312076 2005-10-27
EP16154531.4A EP3045206B2 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Publications (1)

Publication Number Publication Date
DK3284520T3 true DK3284520T3 (da) 2019-09-16

Family

ID=37215098

Family Applications (6)

Application Number Title Priority Date Filing Date
DK17195280.7T DK3284520T3 (da) 2005-04-28 2006-04-28 Polycyklisk carbamoylpyridonderivat med hiv-integrase-hæmmende aktivitet
DK06758843.4T DK1874117T3 (da) 2005-04-28 2006-04-28 Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
DK16154531.4T DK3045206T3 (en) 2005-04-28 2006-04-28 POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES WITH HIV INTEGRASE INHIBITIVE ACTIVITY
DK12159082.2T DK2465580T3 (en) 2005-04-28 2006-04-28 POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES WITH HIV INTEGRASE INHIBITIVE ACTIVITY
DK18166621.5T DK3372281T3 (da) 2005-04-28 2006-04-28 Polycyklisk carbamoylpyridon-derivat med HIV-integrase-hæmmende aktivitet
DK17156762.1T DK3187225T3 (da) 2005-04-28 2006-04-28 Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet

Family Applications After (5)

Application Number Title Priority Date Filing Date
DK06758843.4T DK1874117T3 (da) 2005-04-28 2006-04-28 Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
DK16154531.4T DK3045206T3 (en) 2005-04-28 2006-04-28 POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES WITH HIV INTEGRASE INHIBITIVE ACTIVITY
DK12159082.2T DK2465580T3 (en) 2005-04-28 2006-04-28 POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES WITH HIV INTEGRASE INHIBITIVE ACTIVITY
DK18166621.5T DK3372281T3 (da) 2005-04-28 2006-04-28 Polycyklisk carbamoylpyridon-derivat med HIV-integrase-hæmmende aktivitet
DK17156762.1T DK3187225T3 (da) 2005-04-28 2006-04-28 Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet

Country Status (30)

Country Link
US (22) US8129385B2 (enExample)
EP (9) EP2527007B1 (enExample)
JP (2) JP4295353B2 (enExample)
KR (4) KR101504998B1 (enExample)
AU (1) AU2006239177B8 (enExample)
BE (1) BE2021C519I2 (enExample)
BR (1) BRPI0610030B8 (enExample)
CA (1) CA2606282C (enExample)
CY (7) CY1115151T1 (enExample)
DK (6) DK3284520T3 (enExample)
EA (1) EA014162B1 (enExample)
ES (7) ES2906792T3 (enExample)
FI (1) FIC20210017I1 (enExample)
FR (1) FR14C0041I2 (enExample)
HK (2) HK1249742A1 (enExample)
HU (6) HUE044978T2 (enExample)
IL (4) IL186555A (enExample)
LT (5) LT3284520T (enExample)
LU (2) LU92446I2 (enExample)
MA (1) MA29460B1 (enExample)
MX (2) MX302718B (enExample)
NL (2) NL300676I2 (enExample)
NO (5) NO339525B1 (enExample)
NZ (1) NZ562339A (enExample)
PL (5) PL3372281T3 (enExample)
PT (5) PT3045206T (enExample)
SI (6) SI3284520T1 (enExample)
TW (1) TWI378931B (enExample)
VN (1) VN34404A1 (enExample)
WO (1) WO2006116764A1 (enExample)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004031258D1 (de) 2003-12-24 2011-03-10 Biota Scient Management Polycyclische mittel zur behandlung von infektione
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
PL3372281T3 (pl) * 2005-04-28 2021-12-27 Viiv Healthcare Company Policykliczne pochodne karbamoilopirydonu o aktywności inhibitorowej wobec integrazy HIV
US7741315B2 (en) 2005-05-10 2010-06-22 Merck Sharp & Dohme Corp. HIV integrase inhibitors
US7939537B2 (en) 2005-10-04 2011-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HIV integrase inhibitors
WO2007049675A1 (ja) * 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
PT2220076E (pt) 2007-11-15 2012-04-26 Gilead Sciences Inc Inibidores da replicação do vírus da imunodeficiência humana
NZ585297A (en) * 2007-11-15 2012-06-29 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
BRPI0820307A2 (pt) 2007-11-16 2019-09-24 Boehringer Ingelheim Int inibidores de replicação do vírus da imunodeficiência humana
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2320908B9 (en) * 2008-07-25 2014-06-18 VIIV Healthcare Company Dolutegravir Prodrugs
PT2660239T (pt) * 2008-07-25 2017-02-24 Shionogi & Co Compostos químicos como intermediários sintéticos
JP5551697B2 (ja) * 2008-07-25 2014-07-16 ビーブ・ヘルスケア・カンパニー 化合物
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
CN102239155A (zh) * 2008-12-11 2011-11-09 盐野义制药株式会社 生产麦芽糖醇醚的方法和中间体
EP2376080B1 (en) * 2008-12-11 2017-09-13 Shionogi&Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
CN107011260A (zh) 2008-12-11 2017-08-04 盐野义制药株式会社 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
EP2444400B1 (en) 2009-06-15 2018-03-28 Shionogi&Co., Ltd. Substituted polycyclic carbamoylpyridone derivative
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
EA019558B1 (ru) 2009-10-13 2014-04-30 Эланко Энимал Хэлс Аиэлэнд Лимитед Макроциклические ингибиторы интегразы
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
AU2014202405B2 (en) * 2010-01-27 2016-02-25 Viiv Healthcare Company Antiviral therapy
DK2932970T3 (en) * 2010-01-27 2018-05-28 Viiv Healthcare Co ANTIVIRAL THERAPY
TWI508968B (zh) 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
PE20130010A1 (es) * 2010-02-26 2013-02-05 Japan Tobacco Inc Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
JP5739517B2 (ja) 2010-04-02 2015-06-24 ヤンセン・アールアンドデイ・アイルランド 大環状インテグラーゼ阻害剤
JP5766690B2 (ja) * 2010-04-12 2015-08-19 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
PT3127908T (pt) 2010-08-05 2019-02-04 Shionogi & Co Processo para preparar composto possuindo atividade inibidora de integrase do vih
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
ES2683153T3 (es) * 2010-09-24 2018-09-25 Shionogi & Co., Ltd. Profármaco derivado de carbamoil piridona policíclica sustituida
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
US20140213553A1 (en) * 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US9206197B2 (en) * 2011-09-14 2015-12-08 Mapi Pharma Ltd. Amorphous form of dolutegravir
RU2014113230A (ru) * 2011-10-12 2015-11-20 Шионоги Энд Ко., Лтд. Полициклическое производное пиридона, обладающее ингибирующей активностью в отношении интегразы
SG11201403645VA (en) 2011-12-28 2014-07-30 Global Blood Therapeutics Inc Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
DK2822954T3 (en) * 2012-12-21 2016-05-30 Gilead Sciences Inc POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
CA2890290A1 (en) * 2012-12-27 2014-07-03 Japan Tobacco Inc. Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
US9480655B2 (en) 2013-02-18 2016-11-01 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
WO2014128545A2 (en) 2013-02-19 2014-08-28 Aurobindo Pharma Limited An improved process for the preparation of dolutegravir
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
ES2890077T3 (es) 2013-03-15 2022-01-17 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de la hemoglobina
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201591426A1 (ru) 2013-03-15 2016-02-29 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
US9951079B2 (en) * 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
WO2015001572A2 (en) * 2013-07-04 2015-01-08 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
SMT201700498T1 (it) * 2013-07-12 2017-11-15 Gilead Sciences Inc Composti di carbamoilpiridone policiclici e loro uso per il trattamento di infezioni da hiv
NO2865735T3 (enExample) 2013-07-12 2018-07-21
WO2015009927A1 (en) 2013-07-17 2015-01-22 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
UA117499C2 (uk) 2013-09-27 2018-08-10 Мерк Шарп Енд Доум Корп. Заміщені похідні хінолізину, які можна використовувати як інгібітори інтегрази віл
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015092752A1 (en) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
WO2015089847A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
EP3096763B1 (en) * 2014-01-21 2019-12-25 Laurus Labs Limited Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
PE20160179A1 (es) 2014-02-07 2016-05-20 Global Blood Therapeutics Inc Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido
WO2015139591A1 (zh) * 2014-03-19 2015-09-24 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
IN2014MU00916A (enExample) 2014-03-20 2015-09-25 Cipla Ltd
ZA201503540B (en) * 2014-05-20 2016-10-26 Cipla Ltd Process for preparing polycyclic carbamoyl pyridone derivatives
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (enExample) * 2014-06-20 2018-06-23
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3757105B1 (en) * 2014-08-22 2024-07-24 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
US11311545B2 (en) 2014-10-09 2022-04-26 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016102078A1 (en) 2014-12-24 2016-06-30 Ratiopharm Gmbh Solid state forms of dolutegravir sodium
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
EP3253767A2 (en) 2015-02-06 2017-12-13 Mylan Laboratories Ltd. Processes for the preparation of dolute-gravir
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
EP3285582B1 (en) * 2015-03-26 2020-11-11 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
SI3277691T1 (sl) * 2015-04-02 2019-04-30 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
ES2986814T3 (es) * 2015-04-28 2024-11-12 Shionogi & Co Derivados de piridona policíclicos sustituidos y profármacos de los mismos
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
EP3337479B1 (en) 2015-08-19 2023-12-13 Laurus Labs Limited Novel polymorphs of dolutegravir and salts thereof
BR102016026127A2 (pt) 2015-11-09 2017-05-16 Gilead Sciences Inc composições terapêuticas para o tratamento do vírus da imunodeficiência humana
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
SG11201804647TA (en) 2015-12-04 2018-06-28 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
PT3394069T (pt) 2015-12-21 2019-08-30 Lupin Ltd Processo para a preparação de inibidores de integrase de vih
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
JP7160466B2 (ja) * 2016-06-23 2022-10-25 ヴィーブ ヘルスケア カンパニー 治療薬の送達のための組成物及び方法
BR112019002120A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composição anti-retroviral de várias classes
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
WO2018031987A1 (en) * 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018057408A1 (en) * 2016-09-21 2018-03-29 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
RU2749043C2 (ru) 2016-12-02 2021-06-03 Мерк Шарп И Доум Корп. Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
JOP20190130A1 (ar) * 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
EP3363802B1 (en) 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
CA3053202C (en) 2017-02-16 2022-10-04 Sandoz Ag Crystalline forms of cabotegravir sodium
EP3655106A4 (en) * 2017-07-18 2021-04-21 VIIV Healthcare Company COMBINED INGREDIENTS THERAPY
US11564921B2 (en) 2017-07-21 2023-01-31 Viiv Healthcare Company Regimens for treating HIV infections and AIDS
US20210040116A1 (en) 2017-09-07 2021-02-11 Cipla Limited New Polymorphs of Dolutegravir Sodium
MX2020003469A (es) 2017-10-06 2020-08-03 Shionogi & Co Proceso estereoselectivo para preparar derivados de piridona policiclicos sustituidos.
EP3737359A4 (en) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska ANTIVIRAL MEDICINES AND FORMULATIONS OF THEM
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
CA3132832A1 (en) 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
CR20200645A (es) 2018-05-31 2021-02-05 Shionogi & Co Derivado policiclíco de piridona
IL279051B2 (en) 2018-05-31 2025-01-01 Shionogi & Co Polycyclic carbamoylpyridone derivative
TWI880167B (zh) * 2018-05-31 2025-04-11 日商鹽野義製藥股份有限公司 多環性吡啶并三衍生物
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
CA3117453A1 (en) 2018-10-22 2020-04-30 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
CN120535538A (zh) 2018-11-29 2025-08-26 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
HUE059677T2 (hu) 2019-03-22 2022-12-28 Gilead Sciences Inc Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
JPWO2021107066A1 (enExample) 2019-11-28 2021-06-03
CN114786648A (zh) 2019-12-09 2022-07-22 Viiv保健公司 包含卡博特韦的药物组合物
US11697652B2 (en) * 2020-02-24 2023-07-11 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2022051198A1 (en) 2020-09-01 2022-03-10 Viiv Healthcare Company Combination of cabotegravir and levonorgestrel
KR20230079137A (ko) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
JP2024500322A (ja) 2020-12-07 2024-01-09 ヴィーブ、ヘルスケア、カンパニー 併用療法
HRP20231654T2 (hr) 2021-01-19 2025-01-03 Gilead Sciences, Inc. Supstituirani spojevi piridotriazina i njihove uporabe
TW202313623A (zh) 2021-06-03 2023-04-01 大陸商江蘇恆瑞醫藥股份有限公司 具有整合酶抑制活性的吡啶酮化合物及其藥用用途
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
US20250034607A1 (en) 2021-12-03 2025-01-30 Viiv Healthcare Company Process of Synthesizing (R)-3-aminobutan-1-ol
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
EP4619400A1 (en) * 2023-01-18 2025-09-24 Ascletis Bioscience Co., Ltd. Integrase inhibitor and use thereof
TW202529766A (zh) 2023-09-27 2025-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 3)有限公司 醫藥組合物
WO2025128498A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2025128496A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Crystalline form
WO2025181723A1 (en) 2024-03-01 2025-09-04 ViiV Healthcare UK (No.3) Limited Dosing regimen

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
SK9072000A3 (en) 1997-12-22 2001-03-12 Upjohn Co 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
WO2001095905A1 (fr) † 2000-06-14 2001-12-20 Shionogi & Co., Ltd. Inhibiteur d'enzymes possedant deux ions metal divalents en tant que centres actifs
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
ES2287170T3 (es) 2000-10-12 2007-12-16 MERCK & CO., INC. Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa.
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
DE10178132T1 (de) 2001-08-10 2016-06-23 Shionogi & Co., Ltd. Antivirales Mittel
SI1441734T1 (sl) 2001-10-26 2007-08-31 Angeletti P Ist Richerche Bio Dihidropirimidin karboksamidni inhibitorji HIV-integraze
DE122008000016I1 (de) 2001-10-26 2011-12-01 Angeletti P Ist Richerche Bio N-substituierte hydroxypyrimidinoncarboxamidhemmerder HIV-integrase.
AU2003216049B2 (en) 2002-01-17 2008-07-17 Merck Sharp & Dohme Corp. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
WO2004004657A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7358249B2 (en) 2002-08-13 2008-04-15 Shionogi & Co., Ltd. Heterocyclic compounds having inhibitory activity against HIV integrase
US7517532B2 (en) 2002-09-11 2009-04-14 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
HRP20050593A2 (en) 2002-12-27 2006-03-31 Instituto di Ricerche di Biologia Molecolare P. An Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
US7812016B2 (en) 2003-05-13 2010-10-12 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
AU2003273190A1 (en) * 2003-08-12 2005-02-25 Rachel Beijer Scheduled message service
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
ES2433477T3 (es) 2004-02-11 2013-12-11 Glaxosmithkline Llc Inhibidores de integrasa de VIH
JP2007528394A (ja) 2004-03-09 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
WO2005087766A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
AU2005244157B2 (en) 2004-05-07 2010-11-11 Merck Sharp & Dohme Corp. HIV integrase inhibitors
CA2634499A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
JP5317257B2 (ja) 2005-02-21 2013-10-16 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
CA2600832C (en) 2005-03-31 2011-12-13 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors
PL3372281T3 (pl) * 2005-04-28 2021-12-27 Viiv Healthcare Company Policykliczne pochodne karbamoilopirydonu o aktywności inhibitorowej wobec integrazy HIV
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
US20080214527A1 (en) 2005-08-04 2008-09-04 Takashi Kawasuji Hiv Integrase Inhibitors
WO2007049675A1 (ja) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体

Also Published As

Publication number Publication date
KR20080009733A (ko) 2008-01-29
LT3372281T (lt) 2021-12-10
DK2465580T3 (en) 2014-03-10
PL2465580T3 (pl) 2014-05-30
US20150232479A1 (en) 2015-08-20
EP3187225A1 (en) 2017-07-05
ES2667868T5 (es) 2023-06-01
EP3045206B2 (en) 2023-02-15
SI3284520T1 (sl) 2019-10-30
BE2021C519I2 (enExample) 2025-12-10
SI3187225T1 (sl) 2022-04-29
US20160137666A1 (en) 2016-05-19
CY1122052T1 (el) 2020-10-14
EP3045206A1 (en) 2016-07-20
PT1874117E (pt) 2013-10-17
LU92446I2 (fr) 2015-10-29
EP3284519A1 (en) 2018-02-21
EP3372281A1 (en) 2018-09-12
NZ562339A (en) 2011-01-28
HUE056603T2 (hu) 2022-02-28
BRPI0610030B8 (pt) 2022-01-11
US20240279238A1 (en) 2024-08-22
CY2014024I1 (el) 2015-12-09
MX2007013351A (es) 2008-01-21
IL225207A (en) 2017-11-30
US11267823B2 (en) 2022-03-08
HUS1400039I1 (hu) 2016-08-29
KR101848819B1 (ko) 2018-04-16
NO339525B1 (no) 2016-12-27
IL225206A (en) 2017-11-30
EP2527007A1 (en) 2012-11-28
DK1874117T3 (da) 2013-09-23
LTPA2014021I1 (lt) 2014-07-25
HUS2100023I1 (hu) 2021-07-28
CY1120345T1 (el) 2019-07-10
US20170209454A1 (en) 2017-07-27
US9273065B2 (en) 2016-03-01
AU2006239177B2 (en) 2011-10-20
PL3284520T3 (pl) 2020-01-31
HK1249742A1 (en) 2018-11-09
HK1251191A1 (en) 2019-01-25
PL3372281T3 (pl) 2021-12-27
HUS2100022I1 (hu) 2021-07-28
EP1874117A4 (en) 2009-12-30
MA29460B1 (fr) 2008-05-02
NO20075165L (no) 2007-11-22
US20170224694A1 (en) 2017-08-10
WO2006116764A1 (en) 2006-11-02
DK3372281T3 (da) 2021-09-27
EP2465580B1 (en) 2013-12-18
LTC2465580I2 (enExample) 2022-10-10
EA200702080A1 (ru) 2008-04-28
PT3372281T (pt) 2021-10-14
US20170253616A1 (en) 2017-09-07
EA014162B1 (ru) 2010-10-29
LT3284520T (lt) 2019-09-25
US8129385B2 (en) 2012-03-06
PL1874117T3 (pl) 2014-01-31
LT3045206T (lt) 2018-06-11
KR20160003889A (ko) 2016-01-11
FR14C0041I1 (enExample) 2014-06-27
US20190284208A1 (en) 2019-09-19
SI1874117T1 (sl) 2014-01-31
SI3045206T1 (en) 2018-07-31
US9051337B2 (en) 2015-06-09
NL300676I2 (enExample) 2016-10-11
US20170029438A1 (en) 2017-02-02
DK3045206T3 (en) 2018-05-22
HK1107227A1 (en) 2008-04-03
IL186555A (en) 2016-10-31
HK1172282A1 (en) 2013-04-19
KR101504998B1 (ko) 2015-03-23
NO340111B1 (no) 2017-03-13
US8778943B2 (en) 2014-07-15
JP2008540343A (ja) 2008-11-20
KR101580310B1 (ko) 2016-01-04
ES2437268T3 (es) 2014-01-09
ES2743531T3 (es) 2020-02-19
LTC1874117I2 (lt) 2025-03-25
EP1874117B8 (en) 2014-03-12
MX302718B (es) 2012-08-27
AU2006239177B8 (en) 2012-02-16
ES2667868T3 (es) 2018-05-14
TW200716635A (en) 2007-05-01
EP1874117B1 (en) 2013-08-28
ES2892304T3 (es) 2022-02-03
EP3045206B1 (en) 2018-03-28
NO2023042I1 (no) 2023-11-08
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
AU2006239177A1 (en) 2006-11-02
EP1874117A1 (en) 2008-01-09
NL301109I1 (nl) 2021-09-15
US20160207939A1 (en) 2016-07-21
KR20130133061A (ko) 2013-12-05
PT2465580E (pt) 2014-02-25
SI3372281T1 (sl) 2021-11-30
EP3372281B1 (en) 2021-07-07
IL215788A0 (en) 2011-12-29
EP3284519A8 (en) 2018-04-18
US20170260203A1 (en) 2017-09-14
CY2014024I2 (el) 2025-05-09
KR101363875B1 (ko) 2014-02-21
JP2009079058A (ja) 2009-04-16
DK3187225T3 (da) 2022-02-28
FR14C0041I2 (fr) 2015-11-13
US20120115875A1 (en) 2012-05-10
ES2906792T3 (es) 2022-04-20
LUC00210I2 (enExample) 2022-10-07
IL186555A0 (en) 2008-01-20
CY1115151T1 (el) 2015-12-09
BRPI0610030A2 (pt) 2011-10-11
PT3284520T (pt) 2019-09-10
CA2606282C (en) 2016-04-26
NL301109I2 (nl) 2021-09-15
US20160304535A1 (en) 2016-10-20
HUE044978T2 (hu) 2019-11-28
CY2021016I1 (el) 2021-10-15
US8410103B2 (en) 2013-04-02
KR20140097438A (ko) 2014-08-06
VN34404A1 (en) 2013-07-25
CA2606282A1 (en) 2006-11-02
ES2567197T3 (es) 2016-04-20
BRPI0610030B1 (pt) 2020-09-15
NO2021018I1 (no) 2021-05-10
US20170224695A1 (en) 2017-08-10
FIC20210017I1 (fi) 2021-06-10
NO2017010I2 (no) 2017-03-27
EP3284520B1 (en) 2019-06-05
EP3187225B1 (en) 2022-01-05
CY1124601T1 (el) 2022-07-22
TWI378931B (en) 2012-12-11
US20170145033A1 (en) 2017-05-25
NO2017010I1 (no) 2017-03-27
US20170267693A1 (en) 2017-09-21
LTPA2021512I1 (enExample) 2021-07-12
US20140200209A1 (en) 2014-07-17
PT3045206T (pt) 2018-07-05
MX312216B (en) 2013-08-12
CY2021016I2 (el) 2021-12-31
EP3284520A1 (en) 2018-02-21
US20190152990A1 (en) 2019-05-23
US20130172559A1 (en) 2013-07-04
US20090318421A1 (en) 2009-12-24
EP3187226A1 (en) 2017-07-05
NO20161315A1 (no) 2007-11-22
ES2446324T3 (es) 2014-03-07
PL3045206T3 (pl) 2018-08-31
EP2527007B1 (en) 2016-03-30
SI2465580T1 (sl) 2014-04-30
CY1116331T1 (el) 2017-02-08
HUE037795T2 (hu) 2018-09-28
US20220213121A1 (en) 2022-07-07
JP4295353B2 (ja) 2009-07-15
EP2465580A1 (en) 2012-06-20
US20200339598A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
DK3284520T3 (da) Polycyklisk carbamoylpyridonderivat med hiv-integrase-hæmmende aktivitet
IL190879A0 (en) Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase
DE602006013025D1 (de) Hiv-integrasehemmer
EP1790638A4 (en) CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITION OF HIV INTEGRASE ACTIVITY
IL190952A0 (en) Piperazine derivatives as antimalarial agents
ZA200803423B (en) Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
EP1910363A4 (en) INHIBITORS OF HIV INTEGRASE
ZA200710146B (en) New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
ZA200710147B (en) New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
IL187419A0 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
EP1909578A4 (en) INHIBITORS OF HIV INTEGRASE
EP1910355A4 (en) HIV integrase
DK2044078T3 (da) Camptothecinderivater med antitumoraktivitet